Biocept Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Antonino Morales
Algemeen directeur
US$781.6k
Totale compensatie
Percentage CEO-salaris | 46.8% |
Dienstverband CEO | less than a year |
Eigendom CEO | n/a |
Management gemiddelde ambtstermijn | 3.9yrs |
Gemiddelde ambtstermijn bestuur | 6.1yrs |
Recente managementupdates
Recent updates
Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth
Apr 17Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position
Nov 23Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings
Aug 19Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being
Jul 03Biocept and CLEARED4 ink collaboration agreement
Jun 09Biocept enters COVID-19 testing partnership
Apr 28Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain
Mar 13We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate
Jan 26Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?
Dec 22Biocept's assays viable and sensitive for detecting tumor cells and biomarkers
Nov 20Biocept +4% on COVID-19 testing update
Nov 12Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2023 | n/a | n/a | -US$31m |
Mar 31 2023 | n/a | n/a | -US$37m |
Dec 31 2022 | US$782k | US$366k | -US$32m |
Sep 30 2022 | n/a | n/a | -US$25m |
Jun 30 2022 | n/a | n/a | -US$16m |
Mar 31 2022 | n/a | n/a | -US$8m |
Dec 31 2021 | US$57k | n/a | -US$3m |
Compensatie versus markt: De totale vergoeding ($USD 781.63K ) Antonino } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 652.28K ).
Compensatie versus inkomsten: De vergoeding van Antonino is gestegen terwijl het bedrijf verliesgevend is.
CEO
Antonino Morales (67 yo)
less than a year
Tenure
US$781,631
Compensatie
Mr. Antonino Morales serves as Director of Biocept, Inc., since July 20, 2021 and served as its Interim Chief Financial Officer since February 15, 2022 until June 21, 2023 and serves as its Chief Executive...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO, President & Director | less than a year | US$781.63k | geen gegevens | |
Chief Legal Officer | 1.7yrs | US$773.28k | 0% $ 0 | |
Founder | 26.8yrs | geen gegevens | geen gegevens | |
VP & Controller | less than a year | geen gegevens | geen gegevens | |
Chief Operating Officer | 1.6yrs | geen gegevens | geen gegevens | |
Director of Technology Development | 6.1yrs | geen gegevens | geen gegevens | |
Vice President of Strategy & Corporate Communications | 7yrs | geen gegevens | geen gegevens | |
Senior Medical Director | 8.8yrs | US$577.58k | geen gegevens |
3.9yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van BIOC wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO, President & Director | 2.3yrs | US$781.63k | geen gegevens | |
Independent Director | 13.8yrs | US$65.21k | 0.000080% $ 2.1 | |
Independent Director | 2.3yrs | US$57.26k | 0% $ 0 | |
Independent Director | less than a year | US$13.32k | 0% $ 0 | |
Independent Vice Chairman of the Board | 9.9yrs | US$70.21k | 0.000040% $ 1.1 | |
Member of Clinical Advisory Board | no data | geen gegevens | geen gegevens | |
Independent Chairman of the Board | 13yrs | US$67.71k | 0.00057% $ 15.3 |
6.1yrs
Gemiddelde duur
72yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van BIOC wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).